The Journal of Practical Medicine ›› 2022, Vol. 38 ›› Issue (8): 929-933.doi: 10.3969/j.issn.1006⁃5725.2022.08.003

• Special topic written talk • Previous Articles     Next Articles

Relationship of serum Lp(a)and S100A4 expression level with platelet activation in patients with acute myocardial infarction and its influence on major adverse cardiac events

WAN Jun*,XU Feng,WANG Yulin, CHENG Jinglin,LIANG Youfeng.   

  1. Department of Emergency Medicine,the Second Affiliated Hospital of Anhui Medical University,Hefei 230601,China 

  • Online:2022-04-25 Published:2022-04-25
  • Contact: XU Feng E⁃mail:252758167@qq.com

Abstract:

Objective To investigate the relationship of serum lipoprotein a(Lp(a))and S100 calcium binding protein A4(S100A4)expression level with platelet activation in patients with acute myocardial infarction (AMI)and its influence on major adverse cardiac events. Methods One hundred AMI patients and another 116 healthy individuals in our hospital were enrolled as study group and control group. LP(a),S100A4 and platelet activation related parameters were assessed,and all patients completed one ⁃year follow ⁃up. Risk factors affecting the occurrence of major adverse cardiac events in AMI patients were screened. Results Serum level of Lp(a), S100A4 and platelet activation related parameters were significantly higher in study group than those in control group,showing statistical difference(all P < 0.05). Major adverse cardiac events occurred in 42 AMI patients within 1 year. Serum Lp(A)and S100A4 level was abnormally elevated in patients with major adverse cardiac events. Unconditional logistic regression analysis showed that Lp(A)and S100A4 were risk factors affecting the occurrence of major adverse cardiac events in patients with AMI. Conclusion Serum Lp(a)and S100A4 expres⁃ sion level is positively correlated with platelet activation related parameters,indicating AMI patients with higher serum Lp(A)and S100A4 level suffer a greater risk of major adverse cardiac events.

Key words:

lipoprotein a, S100 calcium binding protein A4, acute myocardial infarction, platelet activation, major adverse cardiac events